Akela Pharma repeats its Fentanyl TAIFUN(R) preclinical toxicology studies

www.akelapharma.com Toronto Stock Exchange Symbol: AKL MONTREAL, July 8 /CNW Telbec/ - Akela Pharma Inc. (TSX: "AKL"), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that as previously requested by the FDA, it has started over again the required inhalation toxicology studies. The studies performed at US based CRO are expected to produce results allowing Akela to start the longer term safety arm of the Fentanyl TAIFUN(R) Phase III clinical trial in patients in the second quarter of 2009. "We are still on track to deliver the required toxicology studies results in time to allow us to meet our previously disclosed regulatory submission timelines of Q1-2010 for the E.U. and Q3-2010 for the U.S." said Dr. Halvor Jaeger, CEO of Akela Pharma Inc. About Akela Pharma... [read full story]